EQUITY RESEARCH MEMO

Proteigene

Generated 5/9/2026

Executive Summary

Conviction (model self-assessment)40/100

Proteigene is a French life sciences company founded in 2001 and headquartered in Saint-Herblain. It operates as a specialized service provider and distributor in the proteomics and metabolomics sectors. The company offers targeted metabolomics analysis covering over a thousand metabolites, along with a comprehensive suite of proteomics services such as protein sequencing, mass spectrometry, and peptide synthesis. Additionally, Proteigene distributes a wide range of laboratory instrumentation and consumables from numerous global vendors to the European research market. By bridging the gap between advanced analytical services and equipment supply, the company supports academic and industrial researchers in their life science endeavors. Despite its long-standing presence in the market, Proteigene remains a private entity with limited public information on financial performance or growth trajectory. The company's business model relies on recurring service contracts and equipment sales, positioning it as a stable but unexciting player in the competitive life science tools landscape. With no disclosed funding rounds or valuation, and a moderate employee count suggested by its established operations, Proteigene is likely a niche operator catering to European research institutions. Its ability to innovate or capture market share will depend on expanding its service portfolio or forming strategic partnerships.

Locked sections
  • · Pipeline Analysis
  • · Competitive Landscape
  • · Catalyst Calendar (full 12-month)
  • · Bull Case
  • · Bear Case
  • · Counterfactual Scenarios
  • · Valuation Notes
  • · SEC Filing Highlights
  • · Insider Activity
  • · Literature Watch
  • · Patent Landscape
  • · Mechanism Cluster Map
  • · Audio Briefing (5 min)